EVO301 Meets Primary Endpoint in Phase 2a Study for Moderate-to-Severe Atopic Dermatitis
Evommune reports positive Phase 2a data for EVO301, showing 55% eczema reduction and a safe profile after 12 weeks of treatment.
/ 2 items
Evommune reports positive Phase 2a data for EVO301, showing 55% eczema reduction and a safe profile after 12 weeks of treatment.
Raymond James begins coverage of Evommune with a Strong Buy rating and a $40 price target, highlighting key Phase 2 clinical catalysts expected in 2026.